Fosfomycin: Efficacy and Challenges in E. coli Treatment

Fosfomycin remains one of the most reliably active antibiotics against E. coli, the bacterium behind the vast majority of urinary tract infections. Even against strains carrying extended-spectrum beta-lactamase (ESBL) enzymes or fluoroquinolone resistance, fosfomycin susceptibility rates in E. coli routinely exceed 90%. That track record, combined with its unique mechanism of action and convenient single-dose oral regimen, has made it a go-to option for uncomplicated UTIs worldwide. But “reliably active” does not mean “without problems,” and a growing body of research points to resistance trends, testing quirks, and clinical scenarios where fosfomycin’s performance gets murkier.

How Fosfomycin Works

Fosfomycin kills bacteria by shutting down the very first step in building their cell wall. Specifically, it permanently disables an enzyme called MurA, which is responsible for kicking off the assembly of peptidoglycan, the mesh-like scaffold that holds a bacterial cell together.¹ Because it locks onto MurA irreversibly, the enzyme cannot recover, and the bacterium cannot repair its wall or build a new one.² No other antibiotic class works at this exact step, which means fosfomycin rarely shares cross-resistance with drugs like penicillins, cephalosporins, or fluoroquinolones. That independence is a major reason it stays active against strains that have already shrugged off multiple other antibiotics.

To reach MurA, fosfomycin hitchhikes into the bacterial cell through two transport proteins that normally shuttle in nutrients: a sugar-phosphate transporter called UhpT and a glycerol-3-phosphate transporter called GlpT. This dependence on active transport is both a strength and a vulnerability. The drug gets concentrated inside the cell at levels far above what’s floating around outside, but mutations that knock out either transporter can block entry altogether.

Activity Against Drug-Resistant E. coli

The clinical value of fosfomycin hinges largely on how well it handles E. coli strains that resist first-line drugs. The evidence here is strong. A study comparing susceptibility testing methods on over 400 ESBL-producing E. coli and Klebsiella strains found fosfomycin showed “very high activity” against all ESBL-producing strains, with excellent agreement across testing methods for E. coli specifically.³ Separately, when researchers tested E. coli isolates from urine and blood that were either ciprofloxacin-resistant or ESBL-producing, all but one isolate was susceptible to fosfomycin regardless of the resistance pattern.⁴

These numbers look reassuring, but they are not universal. Among ESBL-producing E. coli causing UTIs in Wenzhou, China, about 7% of isolates tested resistant to fosfomycin.⁵ And in a pediatric population, resistance rates were dramatically higher: nearly 39% of urinary E. coli isolates from children tested fosfomycin-resistant.⁶ That kind of geographic and population variability means blanket statements about fosfomycin susceptibility can be misleading. Local resistance surveillance data matter.

Treating Uncomplicated UTIs

Uncomplicated lower UTIs in women are fosfomycin’s bread and butter. The standard regimen is a single 3-gram oral dose of fosfomycin trometamol, taken once and done. A systematic review and meta-analysis found that this single dose was comparable to other antibiotic regimens in clearing uncomplicated UTIs, with moderate certainty evidence.⁷ A separate meta-analysis that included pregnant women reached the same conclusion: single-dose fosfomycin matched other antibiotics in both clinical and microbiological resolution, with no serious drug-related side effects.⁸

The picture gets more nuanced when fosfomycin is compared head-to-head against nitrofurantoin, its closest competitor for uncomplicated UTIs. A large randomized trial found that at 28 days after treatment, about 70% of women taking a five-day course of nitrofurantoin maintained clinical resolution, compared with roughly 58% of those who took single-dose fosfomycin. That 12-percentage-point gap was statistically significant.⁹ A smaller prospective study found a clinical cure rate of about 81% for fosfomycin versus 90% for nitrofurantoin, though that difference did not reach statistical significance.¹⁰ An older study comparing single-dose fosfomycin to a seven-day nitrofurantoin course found the two comparable.¹¹

So fosfomycin works, but nitrofurantoin may have a small edge when you look at sustained resolution over weeks. The trade-off is convenience: one dose versus five to seven days of pills. For someone who struggles with adherence or just wants the simplest possible regimen, that single dose has real value.

Pharmacokinetics and Why the Dose Works

After you swallow 3 grams of fosfomycin trometamol, about 42% of the drug gets absorbed, which is considerably better than older calcium-salt formulations that managed only about 12% absorption. Peak blood levels reach roughly 26 mg/L with the trometamol form. Most of the absorbed drug is filtered out through the kidneys and concentrated in urine, with nearly all urinary excretion happening within 12 hours. Around 43% of the oral trometamol dose ends up in the urine.¹² That rapid concentration in urine is what makes a single dose effective for bladder infections: the drug arrives where the bacteria are, at levels high enough to kill them, even though blood levels are modest.

Complicated and Bloodstream Infections

Beyond simple bladder infections, clinicians increasingly reach for intravenous fosfomycin when dealing with complicated UTIs, including kidney infections and cases where bacteria have entered the bloodstream. A prospective cohort study comparing IV fosfomycin to standard antibiotics for complicated E. coli UTIs found similar clinical cure rates: about 65% in the fosfomycin group versus 63% for comparators. Mortality was low in both groups, and fosfomycin performed comparably against pyelonephritis and bacteremic UTIs.¹³ However, non-severe side effects were significantly more common with IV fosfomycin, affecting about 23% of patients versus 8% in the comparator group.

Two landmark trials have shaped the conversation. The ZEUS trial showed IV fosfomycin was noninferior to piperacillin-tazobactam for complicated UTIs and acute pyelonephritis, including in the subgroup with ESBL-producing organisms. The FOREST trial, however, found fosfomycin did not meet noninferiority against ceftriaxone and meropenem in patients with multidrug-resistant bacteremia from a urinary source, partly because more patients had to stop treatment due to side effects.¹⁴ The takeaway from these trials is that IV fosfomycin looks most promising for ESBL-producing, non-bacteremic complicated UTIs in stable patients, where it can spare carbapenems and fluoroquinolones.

How E. coli Develops Resistance

Fosfomycin resistance in E. coli arises through two broad routes: mutations in the bacterium’s own chromosomal genes, and resistance genes acquired from other bacteria on mobile genetic elements called plasmids.

The chromosomal route usually involves the transport genes discussed earlier. When researchers examined fosfomycin-resistant clinical E. coli isolates, nearly all carried at least one genetic change in the uhpA, uhpB, uhpC, uhpT, or glpT genes, which encode or regulate the two transporter proteins the drug needs to enter the cell.¹⁵ If both transporter systems are knocked out, the bacterium essentially locks the door against fosfomycin. These mutations carry a fitness cost, though. In many cases, bacteria that lose these transporters grow less efficiently, which is one reason chromosomal resistance has historically stayed at low levels.

The plasmid-mediated route is more alarming from a public-health perspective. Genes in the fosA family encode enzymes that chemically inactivate fosfomycin. FosA is a glutathione-dependent enzyme that breaks the drug’s active structure before it can reach MurA. Multiple variants of fosA have been identified on transferable plasmids in E. coli, including lineages circulating in France since at least 2012.¹⁶ Newer variants like FosA8 have been found on transferable plasmids in ESBL-producing E. coli from urinary samples, and researchers traced its origin to the chromosomal genes of Leclercia adecarboxylata, an environmental bacterium naturally resistant to fosfomycin.¹⁷ Similarly, the widely distributed fosA3 gene appears to have originated in Kluyvera georgiana, another environmental species.¹⁸

Because plasmid-borne genes can hop between bacteria, these resistance determinants can spread through bacterial populations far more rapidly than chromosomal mutations. The fact that multiple fosA variants have been independently captured from different environmental species suggests a diverse and deep reservoir of potential resistance genes that E. coli can draw on. This is the biggest long-term threat to fosfomycin’s usefulness.

The Testing Problem

One practical challenge that clinicians and lab technicians face is that fosfomycin susceptibility testing is unusually difficult to perform accurately. Standard methods that work well for most antibiotics produce unreliable results with fosfomycin.¹⁹ Neither the major international guidelines body (CLSI) nor its European counterpart (EUCAST) endorses broth microdilution for fosfomycin, which is the default method for nearly every other antibiotic. The reason: fosfomycin produces trailing endpoints and no-growth wells at concentrations below the actual minimum inhibitory concentration, leading to frequent errors in determining whether a strain is susceptible or resistant.²⁰

The recommended reference method is agar dilution supplemented with glucose-6-phosphate, a more labor-intensive process that many clinical labs are not set up to run routinely. This means that in everyday practice, susceptibility results for fosfomycin can be less reliable than for other drugs. A lab report saying a strain is “resistant” could reflect a testing artifact rather than true resistance, and vice versa. For E. coli specifically, the various methods tend to agree reasonably well, but for other organisms like Klebsiella, discrepancies between methods can be dramatic.

Pregnancy and Pediatric Use

Fosfomycin is one of the few antibiotics considered safe in pregnancy for treating UTIs. In a study of pregnant women with urinary infections, about 89% of the bacteria isolated were sensitive to fosfomycin, with E. coli being the dominant pathogen.²¹ Meta-analyses confirm that clinical and microbiological outcomes with fosfomycin in pregnant women match those of other antibiotics, with no serious drug-related adverse events reported.⁸ The single-dose convenience is especially attractive during pregnancy, where minimizing antibiotic exposure and ensuring adherence both matter.

In children, fosfomycin has received renewed interest, particularly for infections caused by multidrug-resistant bacteria. The main pediatric indication is community-acquired lower UTI, and its safety profile in children appears favorable.²² However, clinical experience in pediatric populations is still limited compared with adults, and the surprisingly high fosfomycin resistance rate found among E. coli from children’s UTIs in at least one study is a reminder that pediatric populations may harbor different resistance patterns than adults.

Safety and Side Effects

Oral fosfomycin is generally well tolerated. Gastrointestinal symptoms, mainly diarrhea and nausea, are the most common complaints. For the single-dose oral formulation, these tend to be mild and self-limiting. Intravenous fosfomycin carries a broader side-effect profile, with rash, inflammation at the injection site, low potassium levels, and GI problems being the most frequently reported issues. Serious adverse events like severe allergic reactions, liver toxicity, or blood disorders have been reported but are rare.²³

One aspect of fosfomycin’s safety that is sometimes overlooked is its effect on gut bacteria. A systematic review found that fosfomycin, like many antibiotics, increases the abundance of certain gut bacteria in the Enterobacteriaceae family other than E. coli.²⁴ An older but informative study found that 28 days of oral fosfomycin sharply reduced gut E. coli counts while allowing Klebsiella and Enterobacter populations to expand, though both returned toward baseline within two weeks of stopping the drug.²⁵ For a single-dose regimen, these shifts are likely minimal, but they are worth knowing about for patients on extended or repeated courses.

Cost and Value

Fosfomycin’s single-dose convenience comes at a price, literally. In the US, a cost-effectiveness analysis estimated the total treatment cost of fosfomycin at about $195 under a payer perspective, roughly $50 more than nitrofurantoin and over $80 more than trimethoprim-sulfamethoxazole. Fosfomycin had the highest estimated probability of resolving the infection on the first course (about 88%), compared with roughly 86% for nitrofurantoin and 82% for trimethoprim-sulfamethoxazole. Despite its higher sticker price, the analysis concluded fosfomycin could be considered cost-effective given its higher resolution rate.²⁶

A UK-based analysis found a different dynamic. There, trimethoprim was the most cost-effective option at about £70 per UTI resolved, with fosfomycin close behind at £78. The interesting twist: when local trimethoprim resistance exceeded about 30%, fosfomycin became the more cost-effective choice.²⁷ This finding highlights that the value proposition of fosfomycin is tightly linked to resistance rates. In settings where first-line drugs still work well, fosfomycin is a reasonable but pricier alternative. In settings where resistance has eroded those first-line options, fosfomycin becomes a bargain by comparison.

Combination Therapy and Biofilm Activity

When E. coli is multidrug-resistant, fosfomycin is increasingly studied not as a standalone drug but as a partner in combination regimens. In laboratory testing against eight multidrug-resistant uropathogenic E. coli isolates, double and triple combinations of fosfomycin with imipenem, ciprofloxacin, and tobramycin all showed synergistic effects. Triple combinations were bactericidal within two hours and maintained their killing effect for a full day.²⁸ These are laboratory results, not clinical trials, so it is too early to write specific combination prescriptions based on them. But they suggest fosfomycin could play a useful supporting role in severe resistant infections.

Fosfomycin also shows activity against biofilms, the sticky bacterial communities that form on surfaces like catheters and bladder walls. Exposure to fosfomycin at high concentrations reduced E. coli biofilms by roughly 40-57% for newly forming biofilms and 41-49% for mature ones.²⁹ That is a meaningful reduction, though not eradication, and it helps explain why fosfomycin can be useful for recurrent UTIs where biofilms on the bladder lining may play a role in reinfection.

Where Fosfomycin Fits in the Treatment Landscape

Fosfomycin occupies a distinctive niche. For uncomplicated lower UTIs in women, it is a reliable option, especially when local resistance patterns make trimethoprim-sulfamethoxazole or fluoroquinolones unreliable. Its single-dose regimen is unmatched for convenience. For complicated or bloodstream infections caused by resistant E. coli, IV fosfomycin offers a viable alternative that spares carbapenems, the heavy-artillery antibiotics that infectious disease specialists prefer to keep in reserve. The ZEUS trial data support its use in complicated UTIs and pyelonephritis, though the FOREST trial results urge caution in bacteremic patients.

The vulnerabilities are real but manageable for now. Plasmid-borne resistance genes are spreading, susceptibility testing remains tricky, and the drug’s modest bioavailability limits its usefulness outside the urinary tract. Keeping fosfomycin effective long-term will depend on surveillance, appropriate use, and avoiding the temptation to prescribe it for everything simply because it still works against so many resistant bugs.